Rebiotix starts enrolment in Phase III trial of RBX2660 for C. diff infection

US-based clinical-stage microbiome firm Rebiotix has started patient enrolment in a Phase III clinical trial of RBX2660 to prevent recurrent Clostridium difficile (C. diff) infection.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news